|
| Year | Species | Cells | Factors | Outcome | Reference |
|
| 2019 | Sheep | IPFP-ASCs | Nanofiber polycaprolactone | Promoting chondrogenic differentiation | [47] |
| 2018 | Human | BM-MSCs | Microfluidic model technology | Inducing chondrogenic differentiation | [12] |
| 2018 | Human | IPFP-ASCs | Gelatin scaffolds with aligned holes or random holes | Better chondrogenic differentiation in the gelatin scaffolds with aligned holes than in the gelatin scaffolds with random holes | [11] |
| 2018 | Human | IPFP-ASCs | Coculture with platelet-rich plasma | Failing to promote chondrogenic differentiation | [48] |
| 2018 | Human | ASCs from Lonza (Basel, Switzerland) | Second passage ASCs treated using endothelin-1 | Unfavourable for chondrogenic differentiation | [49] |
| 2018, 2012 | Human | IPFP-ASCs | Coculture with articular chondrocytes in hypoxia (5%) | Promoting chondrogenic differentiation | [50, 51] |
| 2017 | Human | IPFP-ASCs | Coculture with hyaluronic acid nanoparticles | Promoting chondrogenic differentiation and preventing articular cartilage thickening and inflammation | [52] |
| 2017 | Pig | BM-MSCs | Culture with different material scaffolds in hypoxia (5%) | Hypoxia enhances cell viability and the expression of chondrogenic markers, and cellular response is superior with polycaprolactone than with hyaluronic acid | [53] |
| 2017 | Human | IPFP-ASCs | Indirect coculture with osteoarthritis-derived articular chondrocytes | Promoting chondritic phenotypic recovery and IPFP-ASC chondrogenic differentiation in osteoarthritis | [54] |
| 2017 | Human | IPFP-ASCs | Culture of ascorbic acid-treated IPFP-ASCs | The hardness of matrix is unchanged, but the chondrogenic differentiation potential is enhanced | [55] |
| 2017 | Human | IPFP-ASCs and Sc-ASCs | The culture medium containing TGF-β family-related growth factors | Promoting chondrogenic differentiation | [36] |
| 2017 | Human | IPFP-ASCs | Knocking out RHEB | Decreasing chondrogenic and osteogenic differentiation | [56] |
| 2016 | Human | IPFP-ASCs | Porous cartilage extracellular matrix stent containing TGF-β3 | Continuously promoting chondrogenic differentiation | [57] |
| 2017 | Human | IPFP-ASCs | Injectable hydrogel containing TGF-β1 and H2O2 | H2O2 allows the hydrogels to create a high-pressure environment which combined with TGF-β1 continuously promotes chondrogenic differentiation | [58] |
| 2016 | Pig | IPFP-ASCs | Poly(ε-caprolactone) membrane | Inducing stem cells to form cartilage matrix, which enhances chondrogenic differentiation | [59] |
| 2016 | Sheep | IPFP-ASCs | Culture of IPFP-ASCs under low-intensity pulsed ultrasound | Increased expression of cartilage gene | [60] |
| 2016 | Human | IPFP-ASCs | Coculture with rat chondrocytes and acellular dermal matrix | Promoting cartilage formation and infiltration | [61] |
| 2016 | Human | IPFP-ASCs | Coculture with osteoarthritis-derived articular chondrocytes | Failing to promote chondrogenic differentiation | [62] |
| 2015 | Pig | IPFP-ASCs | Culture of IPFP-ASCs under dynamic pressure | Dynamic pressure slightly promotes chondrogenic differentiation and is conducive to structural stability | [63] |
| 2015 | Human | IPFP-ASCs | Implantation of CD44 and IPFP-ASCs into TGF-β3 eluting ECM-derived stents | Producing more sulfated glycosaminoglycan and type II collagen, which promotes chondrogenic differentiation | [64] |
| 2011 | Bear | Sc-ASCs | Pellet culture | Promoting chondrogenic differentiation | [65] |
| 2011 | Cattle | IPFP-ASCs | The 3rd to 12th passage IPFP-ASCs | Unfavourable for chondrogenic differentiation | [7] |
| 2009 | Human | BM-MSCs | Culture of BM-MSCs with dexamethasone | Promoting chondrogenic differentiation by enhancing expression of cartilage extracellular matrix genes | [66] |
| 2003 | Human | IPFP-ASCs | Embedded with fibrin glue followed by culture in cartilage medium | Occurrence of chondrogenic differentiation after 6-week culture | [1] |
|
